Puberty blockers lead almost inevitably to cross-sex hormones
Julia Hartley-Brewer said:
“the vast majority of youngsters who start on these puberty blockers move on to cross sex hormones and that's what the reaction is.”
High continuation rates from blockers to hormones have been reported in some clinic data, and the idea of a medical conveyor belt is an intuitive concern for a parent thinking about irreversibility.
The continuation rate is real, and it is worth understanding what it actually tells us. Young people who go on to receive puberty blockers through a clinical pathway are, by design, those who have shown persistent, consistent gender dysphoria over time: they are not a random sample of every child who ever questioned their gender. When young people are uncertain, they do stop, and the data includes them. So a high rate of continuation is, at least in part, evidence that careful assessment is identifying the right young people, not evidence that the medication itself is steering anyone toward a predetermined outcome. The claim that blockers remove future choice is precisely backwards: what blockers actually do is pause an irreversible process, giving a young person and their family more time to think, not less, and every adolescent who is denied that pause because of a misreading of this data loses the one thing no one can give back to them.
Trans adolescents who are denied access to blockers because their families believe starting treatment removes all future choice, when the evidence supports the opposite: blockers create time and space for reflection.